The buyback accelerates capital return but provides no new operational information. Monitor the final share count upon June 30 settlement for the exact EPS impact. With $3B remaining authorization, the pace of future execution matters more than this single transaction. The filing.
Price Chart
Executive Summary
Boston Scientific entered into a $2B accelerated share repurchase (ASR) agreement with JPMorgan to repurchase its common stock, receiving ~30.4M shares initially (80% of $2B at $52.68 close). The program is part of a previously authorized $5B buyback, with final settlement expected by June 30, 2026. The ASR is expected to add $0.02 to FY2026 adjusted EPS, but the filing provides no other financial data — it is a routine capital allocation announcement with a modest EPS tailwind.
Key Facts
- $2B accelerated share repurchase agreement with JPMorgan Chase Bank announced May 18, 2026
- Initial delivery of ~30.4M shares (~80% of $2B at May 15 close of $52.68)
- Final settlement expected by June 30, 2026; $3B remains under the $5B authorization
- Expected net impact to FY2026 adjusted EPS is $0.02 accretive to prior guidance
Financial Impact
$2.0 billion ASR with ~30.4 million initial shares; $0.02 accretive to FY2026 adjusted EPS
Risk Factors
- ASR final share count depends on VWAP during the term — lower price means more shares retired, but that reflects underlying weakness
- Buyback does not offset operational challenges if future earnings disappoint
Market Snapshot
Investment Themes
Documents Analyzed
This report is based on 5 SEC documents filed with EDGAR.
| Document | Accession Number |
|---|---|
| 8-K Filing (Primary) | 0000885725-26-000042 |
| Exhibit: exhibit991-pressrelease_fi.htm | 0000885725-26-000042 |
| Document: 0000885725-26-000042-index-headers.html | 0000885725-26-000042 |
| Document: 0000885725-26-000042-index.html | 0000885725-26-000042 |
| Document: 0000885725-26-000042.txt | 0000885725-26-000042 |
Filters
| Type | Now | ||||
|---|---|---|---|---|---|
Aug 31, 2026 4w ago | Court Ruling | $48.30 $43.88 | ▼ −9.15% | ▼ −8.96% | $43.23 (−10.50%) |
Aug 26, 2026 5w ago | 8-K | $48.17 $43.72 | ▲ +9.24% | ▲ +10.44% | $43.23 (+10.26%) |
Aug 22, 2026 5w ago | Institutional Cluster | $49.01 $44.92 | ▼ −8.35% | ▼ −9.66% | $43.23 (−11.79%) |
Aug 7, 2026 8w ago | Insider Cluster | $49.31 $47.80 | ▼ −3.06% | ▼ −2.67% | $43.23 (−12.33%) |
Aug 7, 2026 8w ago | Insider Cluster | $49.31 $47.80 | ▼ −3.06% | ▼ −2.67% | $43.23 (−12.33%) |
Aug 5, 2026 8w ago | Insider Cluster | $47.74 $48.37 | ▲ +1.32% | ▲ +1.92% | $43.23 (−9.45%) |
Jul 29, 2026 9w ago | 8-K | $46.04 $48.17 | ▼ −4.63% | ▲ +0.39% | $43.23 (+6.10%) |
Jul 27, 2026 9w ago | 8-K | $46.06 $49.86 | ▲ +8.25% | ▲ +4.87% | $43.23 (−6.14%) |
Jul 27, 2026 9w ago | Court Ruling | $45.51 $49.01 | ▲ +7.69% | ▲ +4.39% | $43.23 (−5.01%) |
Jul 10, 2026 12w ago | Court Ruling | $44.77 $49.30 | ▲ +10.11% | ▲ +7.69% | $43.23 (−3.44%) |
US Market Status
Subscribe to SecBot
Get Real-Time SEC Filing Intelligence
Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.
Try SecBot Free Coming soon: SecBot Pro with alerts, watchlists, and API access